期刊
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
卷 107, 期 5, 页码 873-886出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ijrobp.2020.05.008
关键词
-
资金
- Gattuso-Slaight Personalized Cancer Medicine Fund from the Princess Margaret Cancer Foundation
- Princess Margaret Cancer Centre Discovery Program
- Wharton Family
- Reed Fund
- Conquer Cancer Foundation of ASCO
- Cancer Research Society
- Canadian Cancer Society Research Institute
- Canadian Institutes of Health Research
- International Association for the Study of Lung Cancer
- Joe's Team
- Ontario Molecular Pathology Research Network of the Ontario Institute for Cancer Research
- Lung Cancer Research Foundation
- Canada Foundation for Innovation
- Clinical and Translational Science Center at Weill Cornell Medical Center
- MSKCC [UL1TR00457]
The use of therapeutic radiation is primarily guided by clinicopathologic factors and medical imaging, whereas molecular biomarkers currently play a comparatively minor role in most settings. Liquid biopsies provide a rich source of noninvasive tumor-specific biomarkers and are amenable to repeated and noninvasive assessment. Here, we review the current status of liquid biopsies and their potential impact on the field of radiation oncology. We focus on established and emerging approaches to analyze circulating tumor DNA and circulating tumor cells from peripheral blood. These promising classes of biomarkers could have an outsized impact on cancer management by meaningfully stratifying patients into risk groups, tracking radiation therapy efficacy during and after treatment, and identifying patients with radiosensitive or radioresistant disease. Finally, we highlight opportunities for future investigation including the need for prospective interventional studies employing liquid biopsies to guide the management of radiation therapy-treated patients. (C) 2020 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据